Which has preferable earnings & valuation, ALXO or SLDB?

Solid Biosciences is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ALX Oncology N/A N/A -$101.69M -$1.49 N/A Solid Biosciences N/A N/A -$174.32M -$1.95 N/A

Is ALXO or SLDB more profitable?

Solid Biosciences' return on equity of -73.42% beat ALX Oncology's return on equity. Company Net Margins Return on Equity Return on Assets ALX Oncology N/A -124.06% -85.57% Solid Biosciences N/A -73.42% -61.13%

Does the media favor ALXO or SLDB?

In the previous week, ALX Oncology and ALX Oncology both had 2 articles in the media. ALX Oncology's average media sentiment score of 0.94 beat Solid Biosciences' score of 0.94 indicating that ALX Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ALX Oncology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Solid Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ALXO or ESPR?

In the previous week, Esperion Therapeutics had 2 more articles in the media than ALX Oncology. MarketBeat recorded 4 mentions for Esperion Therapeutics and 2 mentions for ALX Oncology. Esperion Therapeutics' average media sentiment score of 1.42 beat ALX Oncology's score of 0.94 indicating that Esperion Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ALX Oncology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Esperion Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, ALXO or ANRO?

Alto Neuroscience is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ALX Oncology N/A N/A -$101.69M -$1.49 N/A Alto Neuroscience N/A N/A -$63.24M -$2.42 N/A

Is ALXO or ANRO more profitable?

Alto Neuroscience's return on equity of -47.22% beat ALX Oncology's return on equity. Company Net Margins Return on Equity Return on Assets ALX Oncology N/A -124.06% -85.57% Alto Neuroscience N/A -47.22% -38.81%

Which has higher earnings & valuation, ALXO or ANNX?

Annexon is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ALX Oncology N/A N/A -$101.69M -$1.49 N/A Annexon N/A N/A -$206.69M -$1.22 N/A

Is ALXO or ANNX more profitable?

Annexon's return on equity of -101.19% beat ALX Oncology's return on equity. Company Net Margins Return on Equity Return on Assets ALX Oncology N/A -124.06% -85.57% Annexon N/A -101.19% -75.99%

Which has stronger valuation and earnings, VOR or ALXO?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vor Biopharma N/A N/A N/A N/A N/A ALX Oncology N/A N/A -$101.69M -$1.49 N/A

Is VOR or ALXO more profitable?

Vor Biopharma's return on equity of 0.00% beat ALX Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Vor Biopharma N/A N/A N/A ALX Oncology N/A -124.06% -85.57%

Does the media refer more to VOR or ALXO?

In the previous week, Vor Biopharma and Vor Biopharma both had 2 articles in the media. Vor Biopharma's average media sentiment score of 0.94 equaled ALX Oncology'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vor Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ALX Oncology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

ALX Oncology (ALXO) Competitors

$2.04 0.00 (0.00%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$2.03 -0.01 (-0.54%)

As of 04:00 AM Eastern

Compare

ALXO vs. SLDB, ESPR, ANRO, ANNX, and VOR

Should you buy ALX Oncology stock or one of its competitors? MarketBeat compares ALX Oncology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ALX Oncology include Solid Biosciences (SLDB), Esperion Therapeutics (ESPR), Alto Neuroscience (ANRO), Annexon (ANNX), and Vor Biopharma (VOR). These companies are all part of the "pharmaceutical products" industry.

How does ALX Oncology compare to Solid Biosciences?

ALX Oncology (NASDAQ:ALXO) and Solid Biosciences (NASDAQ:SLDB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

ALX Oncology has a beta of 0.44, indicating that its share price is 56% less volatile than the broader market. Comparatively, Solid Biosciences has a beta of 2.43, indicating that its share price is 143% more volatile than the broader market.

98.0% of ALX Oncology shares are owned by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are owned by institutional investors. 21.0% of ALX Oncology shares are owned by company insiders. Comparatively, 2.7% of Solid Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Solid Biosciences is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALX Oncology	N/A	N/A	-$101.69M	-$1.49	N/A
Solid Biosciences	N/A	N/A	-$174.32M	-$1.95	N/A

In the previous week, ALX Oncology and ALX Oncology both had 2 articles in the media. ALX Oncology's average media sentiment score of 0.94 beat Solid Biosciences' score of 0.94 indicating that ALX Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ALX Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Solid Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ALX Oncology presently has a consensus target price of $4.60, indicating a potential upside of 125.49%. Solid Biosciences has a consensus target price of $17.00, indicating a potential upside of 82.99%. Given ALX Oncology's higher possible upside, analysts plainly believe ALX Oncology is more favorable than Solid Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92

Solid Biosciences' return on equity of -73.42% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALX Oncology	N/A	-124.06%	-85.57%
Solid Biosciences	N/A	-73.42%	-61.13%

Summary

ALX Oncology beats Solid Biosciences on 7 of the 13 factors compared between the two stocks.

How does ALX Oncology compare to Esperion Therapeutics?

ALX Oncology (NASDAQ:ALXO) and Esperion Therapeutics (NASDAQ:ESPR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends.

ALX Oncology has a beta of 0.44, suggesting that its stock price is 56% less volatile than the broader market. Comparatively, Esperion Therapeutics has a beta of 1.07, suggesting that its stock price is 7% more volatile than the broader market.

98.0% of ALX Oncology shares are held by institutional investors. Comparatively, 47.4% of Esperion Therapeutics shares are held by institutional investors. 21.0% of ALX Oncology shares are held by insiders. Comparatively, 1.6% of Esperion Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

ALX Oncology currently has a consensus price target of $4.60, suggesting a potential upside of 125.49%. Esperion Therapeutics has a consensus price target of $5.54, suggesting a potential upside of 74.76%. Given ALX Oncology's stronger consensus rating and higher possible upside, analysts clearly believe ALX Oncology is more favorable than Esperion Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Esperion Therapeutics	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Esperion Therapeutics had 2 more articles in the media than ALX Oncology. MarketBeat recorded 4 mentions for Esperion Therapeutics and 2 mentions for ALX Oncology. Esperion Therapeutics' average media sentiment score of 1.42 beat ALX Oncology's score of 0.94 indicating that Esperion Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ALX Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Esperion Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Esperion Therapeutics has higher revenue and earnings than ALX Oncology. Esperion Therapeutics is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALX Oncology	N/A	N/A	-$101.69M	-$1.49	N/A
Esperion Therapeutics	$403.14M	2.03	-$22.68M	-$0.06	N/A

Esperion Therapeutics has a net margin of 0.12% compared to ALX Oncology's net margin of 0.00%. Esperion Therapeutics' return on equity of -0.14% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALX Oncology	N/A	-124.06%	-85.57%
Esperion Therapeutics	0.12%	-0.14%	0.12%

Summary

Esperion Therapeutics beats ALX Oncology on 9 of the 15 factors compared between the two stocks.

How does ALX Oncology compare to Alto Neuroscience?

ALX Oncology (NASDAQ:ALXO) and Alto Neuroscience (NYSE:ANRO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership, media sentiment and risk.

In the previous week, ALX Oncology had 2 more articles in the media than Alto Neuroscience. MarketBeat recorded 2 mentions for ALX Oncology and 0 mentions for Alto Neuroscience. ALX Oncology's average media sentiment score of 0.94 beat Alto Neuroscience's score of 0.00 indicating that ALX Oncology is being referred to more favorably in the media.

Company	Overall Sentiment
ALX Oncology	Positive
Alto Neuroscience	Neutral

98.0% of ALX Oncology shares are owned by institutional investors. 21.0% of ALX Oncology shares are owned by company insiders. Comparatively, 11.3% of Alto Neuroscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Alto Neuroscience's return on equity of -47.22% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALX Oncology	N/A	-124.06%	-85.57%
Alto Neuroscience	N/A	-47.22%	-38.81%

ALX Oncology currently has a consensus target price of $4.60, suggesting a potential upside of 125.49%. Alto Neuroscience has a consensus target price of $35.25, suggesting a potential upside of 31.36%. Given ALX Oncology's higher probable upside, analysts clearly believe ALX Oncology is more favorable than Alto Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Alto Neuroscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

ALX Oncology has a beta of 0.44, meaning that its share price is 56% less volatile than the broader market. Comparatively, Alto Neuroscience has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market.

Alto Neuroscience is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALX Oncology	N/A	N/A	-$101.69M	-$1.49	N/A
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A

Summary

ALX Oncology beats Alto Neuroscience on 7 of the 13 factors compared between the two stocks.

How does ALX Oncology compare to Annexon?

ALX Oncology (NASDAQ:ALXO) and Annexon (NASDAQ:ANNX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, earnings and dividends.

Annexon's return on equity of -101.19% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALX Oncology	N/A	-124.06%	-85.57%
Annexon	N/A	-101.19%	-75.99%

ALX Oncology presently has a consensus target price of $4.60, suggesting a potential upside of 125.49%. Annexon has a consensus target price of $16.00, suggesting a potential upside of 191.28%. Given Annexon's higher probable upside, analysts plainly believe Annexon is more favorable than ALX Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Annexon	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

98.0% of ALX Oncology shares are owned by institutional investors. 21.0% of ALX Oncology shares are owned by company insiders. Comparatively, 10.3% of Annexon shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

ALX Oncology has a beta of 0.44, suggesting that its share price is 56% less volatile than the broader market. Comparatively, Annexon has a beta of 1.18, suggesting that its share price is 18% more volatile than the broader market.

In the previous week, ALX Oncology had 1 more articles in the media than Annexon. MarketBeat recorded 2 mentions for ALX Oncology and 1 mentions for Annexon. Annexon's average media sentiment score of 1.87 beat ALX Oncology's score of 0.94 indicating that Annexon is being referred to more favorably in the news media.

Company	Overall Sentiment
ALX Oncology	Positive
Annexon	Very Positive

Annexon is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALX Oncology	N/A	N/A	-$101.69M	-$1.49	N/A
Annexon	N/A	N/A	-$206.69M	-$1.22	N/A

Summary

ALX Oncology beats Annexon on 7 of the 13 factors compared between the two stocks.

How does ALX Oncology compare to Vor Biopharma?

Vor Biopharma (NASDAQ:VOR) and ALX Oncology (NASDAQ:ALXO) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vor Biopharma	N/A	N/A	N/A	N/A	N/A
ALX Oncology	N/A	N/A	-$101.69M	-$1.49	N/A

Vor Biopharma presently has a consensus price target of $42.25, suggesting a potential upside of 162.42%. ALX Oncology has a consensus price target of $4.60, suggesting a potential upside of 125.49%. Given Vor Biopharma's stronger consensus rating and higher probable upside, research analysts clearly believe Vor Biopharma is more favorable than ALX Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vor Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Vor Biopharma and Vor Biopharma both had 2 articles in the media. Vor Biopharma's average media sentiment score of 0.94 equaled ALX Oncology'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vor Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ALX Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vor Biopharma's return on equity of 0.00% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vor Biopharma	N/A	N/A	N/A
ALX Oncology	N/A	-124.06%	-85.57%

97.3% of Vor Biopharma shares are held by institutional investors. Comparatively, 98.0% of ALX Oncology shares are held by institutional investors. 0.3% of Vor Biopharma shares are held by insiders. Comparatively, 21.0% of ALX Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Vor Biopharma has a beta of 1.71, suggesting that its share price is 71% more volatile than the broader market. Comparatively, ALX Oncology has a beta of 0.44, suggesting that its share price is 56% less volatile than the broader market.

Summary

Vor Biopharma beats ALX Oncology on 7 of the 9 factors compared between the two stocks.

Get ALX Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALXO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALXO vs. The Competition

Export

Metric	ALX Oncology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$274.50M	$3.62B	$6.83B	$12.17B
Dividend Yield	N/A	2.21%	2.66%	6.11%
P/E Ratio	-1.37	21.75	25.89	24.17
Price / Sales	N/A	334.18	546.41	101.77
Price / Cash	N/A	62.10	29.09	36.93
Price / Book	4.25	8.31	10.79	6.38
Net Income	-$101.69M	$23.92M	$3.58B	$337.00M
7 Day Performance	25.15%	1.93%	1.97%	-0.20%
1 Month Performance	7.37%	-0.41%	-0.24%	-1.40%
1 Year Performance	402.71%	65.22%	34.40%	27.76%

ALX Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALXO ALX Oncology	2.955 of 5 stars	$2.04 flat	$4.60 +125.5%	+402.7%	$274.50M	N/A	N/A	40	Gap Down High Trading Volume
SLDB Solid Biosciences	2.5747 of 5 stars	$8.30 -0.4%	$17.00 +104.8%	+96.8%	$820.09M	N/A	N/A	100	Positive News Gap Up
ESPR Esperion Therapeutics	2.4299 of 5 stars	$3.16 +0.3%	$5.54 +75.3%	+219.0%	$811.73M	$403.14M	N/A	200
ANRO Alto Neuroscience	1.9454 of 5 stars	$22.93 +0.8%	$35.25 +53.7%	+1,044.3%	$804.71M	N/A	N/A	N/A	Gap Down
ANNX Annexon	3.6096 of 5 stars	$5.04 +2.9%	$16.00 +217.5%	+127.9%	$802.83M	N/A	N/A	60	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALXO) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ALX Oncology (ALXO) Competitors

ALXO vs. SLDB, ESPR, ANRO, ANNX, and VOR

How does ALX Oncology compare to Solid Biosciences?

Summary

How does ALX Oncology compare to Esperion Therapeutics?

Summary

How does ALX Oncology compare to Alto Neuroscience?

Summary

How does ALX Oncology compare to Annexon?

Summary

How does ALX Oncology compare to Vor Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALXO vs. The Competition

ALX Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ALX Oncology (ALXO) Competitors

ALXO vs. SLDB, ESPR, ANRO, ANNX, and VOR

How does ALX Oncology compare to Solid Biosciences?

Which has more risk and volatility, ALXO or SLDB?

Do insiders & institutionals believe in ALXO or SLDB?

Which has preferable earnings & valuation, ALXO or SLDB?

Does the media favor ALXO or SLDB?

Do analysts prefer ALXO or SLDB?

Is ALXO or SLDB more profitable?

Summary

How does ALX Oncology compare to Esperion Therapeutics?

Which has more risk and volatility, ALXO or ESPR?

Do insiders and institutionals hold more shares of ALXO or ESPR?

Do analysts recommend ALXO or ESPR?

Does the media prefer ALXO or ESPR?

Which has preferable valuation and earnings, ALXO or ESPR?

Is ALXO or ESPR more profitable?

Summary

How does ALX Oncology compare to Alto Neuroscience?

Does the media prefer ALXO or ANRO?

Do insiders & institutionals hold more shares of ALXO or ANRO?

Is ALXO or ANRO more profitable?

Do analysts prefer ALXO or ANRO?

Which has more volatility & risk, ALXO or ANRO?

Which has stronger earnings and valuation, ALXO or ANRO?

Summary

How does ALX Oncology compare to Annexon?

Is ALXO or ANNX more profitable?

Do analysts recommend ALXO or ANNX?

Do insiders and institutionals have more ownership in ALXO or ANNX?

Which has more volatility & risk, ALXO or ANNX?

Does the media favor ALXO or ANNX?

Which has higher earnings & valuation, ALXO or ANNX?

Summary

How does ALX Oncology compare to Vor Biopharma?

Which has stronger valuation and earnings, VOR or ALXO?

Do analysts rate VOR or ALXO?

Does the media refer more to VOR or ALXO?

Is VOR or ALXO more profitable?

Do institutionals & insiders have more ownership in VOR or ALXO?

Which has more risk & volatility, VOR or ALXO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALXO vs. The Competition

ALX Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools